The PI3K/Akt1 pathway enhances steady-state levels of FANCL

Molecular Biology of the Cell

Volumn 24, Issue 16, 2013, Pages 2582-2592

  Dao, Kim Hien T ^a   Rotelli, Michael D ^a   Brown, Brieanna R ^a   Yates, Jane E ^a,b   Rantala, Juha ^c   Tognon, Cristina ^a   Tyner, Jeffrey W ^a   Druker, Brian J ^a   Bagby, Grover C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP L PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; FANCONI ANEMIA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; STEADY STATE; STEM CELL; UBIQUITINATION;

AXIN PROTEIN; CELL LINE; ENZYME ACTIVATION; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP L PROTEIN; GENE EXPRESSION; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HELA CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84882760394     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E13-03-0144     Document Type: Article

References (46)

1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997). beta-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16, 3797-3804.
2. Abrahamsson AE et al. (2009). Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 106, 3925-3929.
3. Alpi AF, Pace PE, Babu MM, Patel KJ (2008). Mechanistic insight into site-restricted monoubiquitination of FANCD2 by Ube2t, FANCL, and FANCI. Mol Cell 32, 767-777.
4. Auerbach AD, Liu Q, Ghosh R, Pollack MS, Douglas GW, Broxmeyer HE (1990). Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion 30, 682-687.
5. Broxmeyer HE, Sherry B, Cooper S, Ruscetti FW, Williams DE, Arosio P, Kwon BS, Cerami A (1991). Macrophage inflammatory protein (MIP)-1 beta abrogates the capacity of MIP-1 alpha to suppress myeloid progenitor cell growth. J Immunol 147, 2586-2594.
6. Chappell WH et al. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2, 135-164.
7. Cole AR, Lewis LP, Walden H (2010). The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. Nat Struct Mol Biol 17, 294-298.
8. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH (2001). Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721-732.
9. Dao KH, Rotelli MD, Petersen CL, Kaech S, Nelson WD, Yates JE, Hanlon Newell AE, Olson SB, Druker BJ, Bagby GC (2012). FANCL ubiquitinates beta-catenin and enhances its nuclear function. Blood 120, 323-334.
10. de Bie P, Ciechanover A (2011). Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ 18, 1393-1402.
11. Dufour C, Corcione A, Svahn J, Haupt R, Poggi V, Beka'ssy AN, Scime R, Pistorio A, Pistoia V (2003). TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102, 2053-2059.
12. Garaycoechea JI, Crossan GP, Langevin F, Daly M, Arends MJ, Patel KJ (2012). Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 571-575.
13. Gluckman E et al. (1989). Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321, 1174-1178.
14. Gurtan AM, Stuckert P, D'Andrea AD (2006). The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. J Biol Chem 281, 10896-10905.
15. Haneline LS, Gobbett TA, Ramani R, Carreau M, Buchwald M, Yoder MC, Clapp DW (1999). Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood 94, 1-8.
16. Hodson C, Cole AR, Lewis LP, Miles JA, Purkiss A, Walden H (2011). Structural analysis of human FANCL, the E3 ligase in the Fanconi anemia pathway. J Biol Chem 286, 32628-32637.
17. Jacome A et al. (2009). Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther 17, 1083-1092.
18. Kee Y, D'Andrea AD (2012). Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest 122, 3799-3806.
19. Kelly PF et al. (2007). Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 15, 211-219.
20. Kockeritz L, Doble B, Patel S, Woodgett JR (2006). Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 7, 1377-1388.
21. Korkina LG, Samochatova EV, Maschan AA, Suslova TB, Cheremisina ZP, Afanas'ev IB (1992). Release of active oxygen radicals by leukocytes of Fanconi anemia patients. J Leukoc Biol 52, 357-362.
22. Langevin F, Crossan GP, Rosado IV, Arends MJ, Patel KJ (2011). Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 475, 53-58.
23. Larghero J, Marolleau JP, Soulier J, Filion A, Rocha V, Benbunan M, Gluckman E (2002). Hematopoietic progenitor cell harvest and functionality in Fanconi anemia patients. Blood 100, 3051.
24. Li J et al. (2007). TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest 117, 3283-3295.
25. Li X, Yang Y, Yuan J, Hong P, Freie B, Orazi A, Haneline LS, Clapp DW (2004). Continuous in vivo infusion of interferon-gamma (IFN-gamma) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc-/- mice. Blood 104, 1204-1209.
26. Li X et al. (2005). Ex vivo culture of Fancc-/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood 105, 3465-3471.
27. Lim KL et al. (2005). Parkin mediates nonclassical, proteasomal- independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 25, 2002-2009.
28. Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE (1999). Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther 10, 2337-2346.
29. Livingston CM, Ifrim MF, Cowan AE, Weller SK (2009). Virus-induced chaperone-enriched (VICE) domains function as nuclear protein quality control centers during HSV-1 infection. PLoS Pathog 5, e1000619.
30. Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, Evangelisti C (2012). The emerging multiple roles of nuclear Akt. Biochim Biophys Acta 1823, 2168-2178.
31. Meetei AR et al. (2003). A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 35, 165-170.
32. Meetei AR, Yan Z, Wang W (2004). FANCL replaces BRCA1 as the likely ubiquitin ligase responsible for FANCD2 monoubiquitination. Cell Cycle 3, 179-181.
33. Moldovan GL, D'Andrea AD (2009). How the Fanconi anemia pathway guards the genome. Annu Rev Genet 43, 223-249.
34. Polak R, Buitenhuis M (2012). The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 119, 911-923.
35. Rantala J, Kwon S, Korkola J, Gray J (2013). Expanding the diversity of imaging-based RNAi screen applications using cell spot microarrays. Microarrays 2, 97-114.
36. Raya A, Rodriguez-Piza I, Navarro S, Richaud-Patin Y, Guenechea G, Sanchez-Danes A, Consiglio A, Bueren J, Izpisua Belmonte JC (2010). A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. Nat Protoc 5, 647-660.
37. Rosado IV, Langevin F, Crossan GP, Takata M, Patel KJ (2011). Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. Nat Struct Mol Biol 18, 1432-1434.
38. Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E (1994). Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. Blood 83, 1216-1225.
39. Scarpa M, Rigo A, Momo F, Isacchi G, Novelli G, Dallapiccola B (1985). Increased rate of superoxide ion generation in Fanconi anemia erythrocytes. Biochem Biophys Res Commun 130, 127-132.
40. Schultz JC, Shahidi NT (1993). Tumor necrosis factor-alpha overproduction in Fanconi's anemia. Am J Hematol 42, 196-201.
41. Seki S et al. (2007). A requirement of FancL and FancD2 monoubiquitination in DNA repair. Genes Cells 12, 299-310.
42. Si Y et al. (2006). Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice. Blood 108, 4283-4287.
43. Tulpule A, Lensch MW, Miller JD, Austin K, D'Andrea A, Schlaeger TM, Shimamura A, Daley GQ (2010). Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood 115, 3453-3462.
44. Yilmaz OH, Morrison SJ (2008). The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. Blood Cells Mol Dis 41, 73-76.
45. Zhang X et al. (2008). Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A. Blood 112, 1683-1686.
46. Zhang X, Sejas DP, Qiu Y, Williams DA, Pang Q (2007). Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. J Cell Sci 120, 1572-1583.